Austar Lifesciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Austar Lifesciences.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Life Sciences earnings growth | 25.6% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive
Apr 18Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?
Mar 28Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump
Feb 12Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues
Dec 22We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt
Sep 28Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden
Mar 31Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 19Is Austar Lifesciences (HKG:6118) A Risky Investment?
Apr 06Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 24With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting
Sep 27If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late
May 31Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Mar 31Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?
Mar 01Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Feb 01Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 11Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Dec 21Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?
Dec 07Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like
Nov 23In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Austar Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 1,764 | -33 | N/A | N/A | N/A |
6/30/2023 | 2,089 | 2 | -136 | -60 | N/A |
3/31/2023 | 2,159 | 45 | -155 | -49 | N/A |
12/31/2022 | 2,229 | 87 | -175 | -38 | N/A |
9/30/2022 | 2,246 | 96 | -233 | -81 | N/A |
6/30/2022 | 2,264 | 105 | -291 | -125 | N/A |
3/31/2022 | 2,139 | 191 | -255 | -114 | N/A |
12/31/2021 | 2,015 | 277 | -219 | -103 | N/A |
9/30/2021 | 1,824 | 258 | -128 | -32 | N/A |
6/30/2021 | 1,633 | 238 | -36 | 40 | N/A |
3/31/2021 | 1,465 | 136 | -26 | 46 | N/A |
12/31/2020 | 1,296 | 33 | -15 | 52 | N/A |
9/30/2020 | 1,193 | 25 | -11 | 48 | N/A |
6/30/2020 | 1,089 | 17 | -7 | 43 | N/A |
3/31/2020 | 1,069 | 12 | 8 | 41 | N/A |
12/31/2019 | 1,049 | 8 | 23 | 38 | N/A |
9/30/2019 | 1,007 | 8 | -33 | -4 | N/A |
6/30/2019 | 966 | 8 | -89 | -46 | N/A |
3/31/2019 | 891 | 4 | -104 | -62 | N/A |
12/31/2018 | 817 | 0 | -119 | -78 | N/A |
9/30/2018 | 724 | -16 | -63 | -37 | N/A |
6/30/2018 | 631 | -33 | -7 | 4 | N/A |
3/31/2018 | 589 | -43 | -11 | -1 | N/A |
12/31/2017 | 547 | -54 | -16 | -6 | N/A |
9/30/2017 | 587 | -43 | N/A | -20 | N/A |
6/30/2017 | 628 | -32 | N/A | -33 | N/A |
3/31/2017 | 650 | -25 | N/A | -32 | N/A |
12/31/2016 | 673 | -19 | N/A | -30 | N/A |
9/30/2016 | 648 | -17 | N/A | 3 | N/A |
6/30/2016 | 624 | -16 | N/A | 37 | N/A |
3/31/2016 | 626 | -5 | N/A | 49 | N/A |
12/31/2015 | 628 | 6 | N/A | 62 | N/A |
9/30/2015 | 640 | 24 | N/A | 26 | N/A |
6/30/2015 | 652 | 43 | N/A | -9 | N/A |
3/31/2015 | 666 | 54 | N/A | -37 | N/A |
12/31/2014 | 680 | 65 | N/A | -64 | N/A |
9/30/2014 | 676 | 58 | N/A | -51 | N/A |
6/30/2014 | 672 | 51 | N/A | -37 | N/A |
3/31/2014 | 689 | 52 | N/A | 17 | N/A |
12/31/2013 | 705 | 54 | N/A | 71 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6118's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if 6118's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 6118's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 6118's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 6118's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6118's Return on Equity is forecast to be high in 3 years time